Skip to main content
. 2023 Mar 1;15(1):2184197. doi: 10.1080/19420862.2023.2184197

Figure 8.

Figure 8.

(a) BLI epitope binning of three lead antibodies and vitronectin to uPAR. The binding of each antibody to uPAR resulted in a decreased wavelength shift in the last association step (VN-added) demonstrating the competitive blocking of VN binding by each antibody. (b) BLI competition assay reveals 8163 and 3159 have distinct binding sites, and 11857 has a partially overlapping epitope with 8163 and 3159.